16 research outputs found
Using cluster analysis with principal component analysis to study the iron metabolism in polycythemia vera
Background. Iron deficiency is a common complication in patients with polycythemia vera (PV). Unfortunately, little is known about the pathomechanisms of iron deficiency in PV. There have been no studies in the last decade documenting iron disorders in PV, despite progress in understanding the iron metabolism and new laboratory techniques measuring iron parameters.Objectives. The aim of this study was to assess the relationships between iron metabolism parameters, haematological and biochemical factors and clinical attributes in polycythemia vera patients with the use of cluster analysis (CA) and principal component analysis (PCA).Patients and methods. The study was performed on 60 patients (F/M 26/34) aged 38–84 (66 ± 10) years. The following parameters were determined in blood samples: hepcidin, prohepcidin, iron, total iron binding capacity (TIBC), unsaturated iron binding capacity (UIBC), ferritin, soluble transferrin receptor (sTfR), transferrin saturation (TfS), complete blood cell count, erythropoietin (Epo), uric acid, lactate dehydrogenase (LDH).Results. The CA divided all the 17 parameters into three clusters and showed that hepcidin concentrationis related to the duration of hydroxyurea therapy. PCA also revealed a positive correlation between hepcidin and therapy duration.Conclusions. We demonstrated that CA and PCA are efficacious methods for assessing the relationship between iron metabolism parameters and clinical attributes in PV patients
Mathematical techniques for the protection of patient's privacy in medical databases
In modern society, keeping the balance between privacy and public access to information is becoming a widespread problem more and more often. Valid data is crucial for many kinds of research, but the public good should not be achieved at the expense of individuals.
While creating a central database of patients, the CSIOZ wishes to provide statistical information for selected institutions. However, there are some plans to extend the access by providing the statistics to researchers or even to citizens. This might pose a significant risk of disclosure of some private, sensitive information about
individuals. This report proposes some methods to prevent data leaks.
One category of suggestions is based on the idea of modifying statistics, so that they would maintain importance for statisticians and at the same time guarantee the protection of patient's privacy.
Another group of proposed mechanisms, though sometimes difficult to implement, enables one to obtain precise statistics, while restricting such queries which might reveal sensitive information
Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases : results of a multi-center questionnaire study
Objectives: Biologics are medications widely applied in the management of inflammatory rheumatic
diseases. The drugs were found to be effective but their application is associated with some
disadvantages. Medication with biologics is relatively expensive, and in Poland, it is carried out in
specialized centers. The study was designed to evaluate various aspects of satisfaction and dissatisfaction
of Polish patients treated with biologics.
Material and methods: An anonymous questionnaire was distributed in 23 Polish rheumatological
centers involved in the treatment; 1212 returned questionnaires were used for analysis. Responses
were received from 606 patients with rheumatoid arthritis, 427 with ankylosing spondylitis,
117 psoriatic arthritis, and 62 adult patients with juvenile idiopathic arthritis (in whom administration
of the drugs had been introduced before they were 18 years old). The investigated group
constituted about one-fifth of all rheumatic patients on biologics in Poland.
Results: A beneficial or very beneficial influence of the medication on the state of physical health
was found mostly in patients with rheumatoid arthritis (51.3 and 30.5%) and ankylosing spondylitis
(51.0 and 36.8%). Family life was improved by the treatment especially in patients with ankylosing
spondylitis (40.7 and 35.6% beneficial and very beneficial, respectively), sleep quality and sexual
life mostly in those with ankylosing spondylitis (beneficial/very beneficial influence 41.5/38.4, and
38.7/23.9, respectively). There was a rather small influence of biological treatment on the financial
situation of the patients. In general, satisfaction with the treatment was evaluated as positive or
very positive in 88% of all investigated patients.
In a significant part of the patients, transportation to the medical center was considered as a disadvantage
of the treatment. About one-third of the patients considered laboratory and imaging tests
to be done before initiation of the medication as a difficulty, and for about 40% waiting time for
qualification for the medication was a significant disadvantage. The route of drug administration
was without importance for 4/5 of the patients.
Conclusions: Summing up, the results were similar in the patients suffering from various diseases
although those with psoriatic arthritis felt the highest satisfaction (possibly due to the positive
aesthetic effect), and those with ankylosing spondylitis had significant improvement in sexual life
(probably due to younger age). Relatively low satisfaction was found in patients with juvenile idiopathic
arthritis. There was a small influence of medication on financial status of the patients. Application
of biologics has few disadvantages and most of them are associated with the organization of
health services (waiting time for the tests, transportation to the medical centers)
Recommended from our members
EPMA-World Congress 2015: Bonn, Germany. 3-5 September 2015
Table of contents A1 Predictive and prognostic biomarker panel for targeted application of radioembolisation improving individual outcomes in hepatocellular carcinoma Jella-Andrea Abraham, Olga Golubnitschaja A2 Integrated market access approach amplifying value of “Rx-CDx” Ildar Akhmetov A3 Disaster response: an opportunity to improve global healthcare Russell J. Andrews, Leonidas Quintana A4 USA PPPM: proscriptive, profligate, profiteering medicine-good for 1 % wealthy, not for 99 % unhealthy Russell J. Andrews A5 The role of IDO in a murine model of gingivitis: predictive and therapeutic potentials Babak Baban, Jun Yao Liu, Xu Qin, Tailing Wang, Mahmood S. Mozaffari A6 Specific diets for personalised treatment of diabetes type 2 Viktoriia V. Bati, Tamara V. Meleshko, Olga B. Levchuk, Nadiya V. Boyko A7 Towards personalized physiotherapeutic approach Joanna Bauer, Ewa Boerner, Halina Podbielska A8 Cells, animal, SHIME and in silico models for detection and verification of specific biomarkers of non-communicable chronic diseases Alojz Bomba, Viktor O. Petrov, Volodymyr G. Drobnych, Rostyslav V. Bubnov, Oksana M. Bykova, Nadiya V. Boyko A9 INTERACT-chronic care model: Self-treatment by patients with decision support e-Health solution Hans-Peter Brunner-La Rocca, Lutz Fleischhacker, Olga Golubnitschaja, Frank Heemskerk, Thomas Helms, Tiny Jaarsma, Judita Kinkorova, Jan Ramaekers, Peter Ruff, Ivana Schnur, Emilio Vanoli, Jose Verdu A10 PPPM in cardiovascular medicine in 2015 Hans-Peter Brunner-La Rocca A11 Magnetic resonance imaging of nanoparticles in mice, potential for theranostic and contrast media development – pilot results Rostyslav V. Bubnov, Sergiy A. Grabovetskyi, Olena M. Mykhalchenko, Natalia O. Tymoshok, Oleksandr B. Shcherbakov, Igor P. Semeniv, Mykola Y. Spivak A12 Ultrasound diagnosis for diabetic neuropathy - comparative study Rostyslav V. Bubnov, Tetyana V. Ostapenko A13 Ultrasound for stratification patients with diabetic foot ulcers for prevention and personalized treatment - pilot results Rostyslav V. Bubnov, Nazarii M. Kobyliak, Nadiya M. Zholobak, Mykola Ya. Spivak A14 Project ImaGenX – designing and executing a questionnaire on environment and lifestyle risk of breast cancer John Paul Cauchi A15 Genomics – a new structural brand of predictive, preventive and personalized medicine or the new driver as well? Dmitrii Cherepakhin, Marina Bakay, Artem Borovikov, Sergey Suchkov A16 Survey of questionnaires for evaluation of the quality of life in various medical fields Barbara Cieślik, Agnieszka Migasiewicz, Maria-Luiza Podbielska, Markus Pelleter, Agnieszka Giemza, Halina Podbielska A17 Personalized molecular treatment for muscular dystrophies Sebahattin Cirak A18 Secondary mutations in circulating tumour DNA for acquired drug resistance in patients with advanced ALK + NSCLC Marzia Del Re, Paola Bordi, Valentina Citi, Marta Palombi, Carmine Pinto, Marcello Tiseo, Romano Danesi A19 Recombinant species-specific FcεRI alpha proteins for diagnosis of IgE-mediated allergies in dogs, cats and horses Lukas Einhorn, Judit Fazekas, Martina Muhr, Alexandra Schoos, Lucia Panakova, Ina Herrmann, Krisztina Manzano-Szalai, Kumiko Oida, Edda Fiebiger, Josef Singer, Erika Jensen-Jarolim A20 Global methodology for developmental neurotoxicity testing in humans and animals early and chronically exposed to chemical contaminants Arpiné A. Elnar, Nadia Ouamara, Nadiya Boyko, Xavier Coumoul, Jean-Philippe Antignac, Bruno Le Bizec, Gauthier Eppe, Jenny Renaut, Torsten Bonn, Cédric Guignard, Margherita Ferrante, Maria Liusa Chiusano, Salvatore Cuzzocrea, Gerard O'Keeffe, John Cryan, Michelle Bisson, Amina Barakat, Ihsane Hmamouchi, Nasser Zawia, Anumantha Kanthasamy, Glen E. Kisby, Rui Alves, Oscar Villacañas Pérez, Kim Burgard, Peter Spencer, Norbert Bomba, Martin Haranta, Nina Zaitseva, Irina May, Stéphanie Grojean, Mathilde Body-Malapel, Florencia Harari, Raul Harari, Kristina Yeghiazaryan, Olga Golubnitschaja, Vittorio Calabrese, Christophe Nemos, Rachid Soulimani A21 Mental indicators at young people with attributes hypertension and pre-hypertension Maria E. Evsevyeva, Elena A. Mishenko, Zurida V. Kumukova, Evgeniy V. Chudnovsky, Tatyana A. Smirnova A22 On the approaches to the early diagnosis of stress-induced hypertension in young employees of State law enforcement agencies Maria E. Evsevyeva, Ludmila V. Ivanova, Michail V. Eremin, Maria V. Rostovtseva A23 Сentral aortic pressure and indexes of augmentation in young persons in view of risk factors Maria E. Evsevyeva, Michail V. Eremin, Vladimir I. Koshel, Oksana V. Sergeeva, Nadesgda M. Konovalova A24 Breast cancer prediction and prevention: Are reliable biomarkers in horizon? Shantanu Girotra, Olga Golubnitschaja A25 Flammer Syndrome and potential formation of pre-metastatic niches: A multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease Olga Golubnitschaja, Manuel Debald, Walther Kuhn, Kristina Yeghiazaryan, Rostyslav V. Bubnov, Vadym M. Goncharenko, Ulyana Lushchyk, Godfrey Grech, Katarzyna Konieczka A26 Innovative tools for prenatal diagnostics and monitoring: improving individual pregnancy outcomes and health-economy in EU Olga Golubnitschaja, Jan Jaap Erwich, Vincenzo Costigliola, Kristina Yeghiazaryan, Ulrich Gembruch A27 Immunohistochemical assessment of APUD cells in endometriosis Vadym M. Goncharenko, Vasyl O. Beniuk, Olga V. Kalenska, Rostyslav V. Bubnov A28 Updating personalized management algorithm of endometrial hyperplasia in pre-menopause women Vadym M. Goncharenko, Vasyl O. Beniuk, Rostyslav V. Bubnov, Olga Melnychuk A29 The personified treatment approach of polimorbid patients with periodontal inflammatory diseases Irina A. Gorbacheva, Lyudmila Y. Orekhova, Vadim V. Tachalov A30 Ukrainian experience in hybrid war – the challenge to update algorithms for personalized care and early prevention of different military injuries Olena I. Grechanyk, Rizvan Ya. Abdullaiev, Rostyslav V. Bubnov A31 Tear fluid biomarkers: a comparison of tear fluid sampling and storage protocols Suzanne Hagan, Eilidh Martin, Ian Pearce, Katherine Oliver A32 The correlation of dietary habits with gingival problems during menstruation Cenk Haytac, Fariz Salimov, Servin Yoksul, Anatoly A. Kunin, Natalia S. Moiseeva A33 Genomic medicine in a contemporary Spanish population of prostate cancer: our experience Bernardo Herrera-Imbroda, Sergio del Río-González, Maria Fernanda Lara, Antonia Angulo, Francisco Javier Machuca Santa-Cruz A34 Challenges, opportunities and collaborations for personalized medicine applicability in uro-oncological disease Bernardo Herrera-Imbroda, Sergio del Río-González, Maria Fernanda Lara A35 Metabolic hallmarks of cancer as targets for a personalized therapy John Ionescu A36 Influence of genetic polymorphism as a predictor of the development of periodontal disease in patients with gastric ulcer and 12 duodenal ulcer Alfiya Z. Isamulaeva, Anatoly A. Kunin, Shamil Sh. Magomedov, Aida I. Isamulaeva A37 Challenges in diabetic macular edema Tatjana Josifova A38 Overview of the EPMA strategies in laboratory medicine relevant for PPPM Marko Kapalla, Juraj Kubáň, Olga Golubnitschaja, Vincenzo Costigliola A39 EPMA initiative for effective organization of medical travel: European concepts and criteria Vincenzo Costigliola, Marko Kapalla, Juraj Kubáň, Olga Golubnitschaja A40 Design and innovation in e-textiles: implications for PPPM Anthony Kent, Tom Fisher, Tilak Dias A41 Biobank in Pilsen as a member of national node BBMRI_CZ Judita Kinkorová, Ondřej Topolčan A42 Big data in personalized medicine: hype and hope Matthias Kohl A43 The 3P approach as the platform of the European Dentistry Department (DPPPD) Anatoly A. Kunin, Natalia S. Moiseeva A44 The endometrium cytokine patterns for predictive diagnosis of proliferation severity and cancer prevention Andrii I. Kurchenko, Vasyl A. Beniuk, Vadym M. Goncharenko, Rostyslav V. Bubnov, Nadiya V. Boyko, Andriy M. Strokan A45 A monocyte-based in-vitro system for testing individual responses to the implanted material: future for personalized implant construction Julia Kzhyshkowska, Alexandru Gudima, Ksenia S. Stankevich, Victor D. Filimonov4, Harald Klüter, Evgeniya M. Mamontova, Sergei I. Tverdokhlebov A46 Prediction and prevention of adverse health effects by meteorological factors: Biomarker patterns and creation of a device for self-monitoring and integrated care Ulyana B. Lushchyk, Viktor V. Novytskyy, Igor P. Babii, Nadiya G. Lushchyk, Lyudmyla S. Riabets, Ivanna I. Legka A47 Targeting "disease signatures" towards personalized healthcare Mira Marcus-Kalish, Alexis Mitelpunkt, Tal Galili, Neta Shachar, Yoav Benjamini A48 Influence of the skin imperfection on the personal quality of life and possible tools for objective diagnosis Agnieszka Migasiewicz, Markus Pelleter, Joanna Bauer, Ewelina Dereń, Halina Podbielska A49 The new direction in caries prevention based on the ultrastructure of dental hard tissues and filling materials Natalia S. Moiseeva, Anatoly A. Kunin, Dmitry A. Kunin A50 The use of LED radiation in prevention of dental diseases Natalia S. Moiseeva, Yury A. Ippolitov, Dmitry A. Kunin, Alexei N. Morozov, Natalia V. Chirkova, Nakhid T. Aliev A51 Status of endothelial progenitor cells in diabetic nephropathy: predictive and preventive potentials Mahmood S. Mozaffari, Jun Yao Liu, Babak Baban A52 The status of glucocorticoid-induced leucine zipper protein in salivary gland in Sjögren’s syndrome: predictive and personalized treatment potentials Mahmood S. Mozaffari, Jun Yao Liu, Rafik Abdelsayed, Xing-Ming Shi, Babak Baban A53 Maximal aerobic capacity - important quality marker of health Jaroslav Novák, Milan Štork, Václav Zeman A54 The EMPOWER project: laboratory medicine and Horizon 2020 Wytze P. Oosterhuis, Elvar Theodorsson A55 Personality profile manifestations in patient’s attitude to oral care and adherence to doctor’s prescriptions Lyudmila Y. Orekhova, Tatyana V. Kudryavtseva, Elena R. Isaeva, Vadim V. Tachalov, Ekaterina S. Loboda A56 Results of an European survey on personalized medicine addressed to directions of laboratory medicine Mario Pazzagli, Francesca Malentacchi, Irene Mancini, Ivan Brandslund, Pieter Vermeersch, Matthias Schwab, Janja Marc, Ron H.N. van Schaik, Gerard Siest, Elvar Theodorsson, Chiara Di Resta A57 MCI or early dementia predictive speech based diagnosis techniques Matus Pleva, Jozef Juhar A58 Personalized speech based mobile application for eHealth Matus Pleva, Jozef Juhar A59 Circulating tumor cell-free DNA as the biomarker in the management of cancer patients Jiří Polívka jr., Filip Janků, Martin Pešta, Jan Doležal, Milena Králíčková, Jiří Polívka A60 Complex stroke care – educational programme in Stroke Centre University Hospital Plzen Jiří Polívka, Alena Lukešová, Nina Müllerová, Petr Ševčík, Vladimír Rohan A61 Sleep apnea and sleep fragmentation contribute to brain aging Kneginja Richter, Lence Miloseva, Günter Niklewski A62 Personalised approach for sleep disturbances in shift workers Kneginja Richter, Jens Acker, Guenter Niklewski A63 Medical travel and innovative PPPM clusters: new concept of integration Olga Safonicheva, Vincenzo Costigliola A64 Medical travel and women health Olga Safonicheva A65 Continuity of generations in the training of specialists in the field of reconstructive microsurgery Maxim Sautin, Janna Sinelnikova, Sergey Suchkov A66 Telemonitoring of stroke patients – empirical evidence of individual risk management results from an observational study in Germany Songül Secer, Stephan von Bandemer A67 Women’s increasing breast cancer risk with n-6 fatty acid intake explained by estrogen-fatty acid interactive effect on DNA damage: implications for gender-specific nutrition within personalized medicine Niva Shapira A68 Cytobacterioscopy of the gingival crevicular fluid as a method for preventive diagnosis of periodontal diseases Aleksandr Shcherbakov, Anatoly A. Kunin, Natalia S. Moiseeva A69 Use of specially treated composites in dentistry to avoid violations of aesthetics Bogdan R. Shumilovich, Zhanna Lipkind, Yulia Vorobieva, Dmitry A. Kunin, Anastasiia V. Sudareva A70 National eHealth system – platform for preventive, predictive and personalized diabetes care Ivica Smokovski, Tatjana Milenkovic A72 The common energy levels of Prof. Szent-Györgyi, the intrinsic chemistry of melanin, and the muscle physiopathology. Implications in the context of Preventive, Predictive, and Personalized Medicine Arturo Solís-Herrera, María del Carmen Arias-Esparza, Sergey Suchkov A73 Plurality and individuality of hepatocellular carcinoma: PPPM perspectives Krishna Chander Sridhar, Olga Golubnitschaja A74 Strategic aspects of higher medical education reforms to secure newer educational platforms for getting biopharma professionals matures Maria Studneva, Sihong Song, James Creeden, Мark Мandrik, Sergey Suchkov A75 Overview of the strategies and activities of the European Federation of Clinical Chemistry and Laboratory Medicine, (EFLM) Elvar Theodorsson, EFLM A76 New spectroscopic techniques for point of care label free diagnostics Syed A. M. Tofail A77 Tumor markers for personalized medicine and oncology - the role of Laboratory Medicine Ondřej Topolčan, Judita Kinkorová, Ondřej Fiala, Marie Karlíková, Šárka Svobodová, Radek Kučera, Radka Fuchsová, Vladislav Třeška, Václav Šimánek, Ladislav Pecen, Jan Šoupal, Štěpán Svačina2 A78 Modern medical terminology (MMT) as a driver of the global educational reforms Evgeniya Tretyak, Maria Studneva, Sergey Suchkov A79 Juvenile hypertension; the relevance of novel predictive, preventive and personalized assessment of its determinants Francesca M. Trovato, G. Fabio Martines, Daniela Brischetto, Daniela Catalano, Giuseppe Musumeci, Guglielmo M. Trovato A80 Proteomarkers Biotech George Th. Tsangaris, Athanasios K. Anagnostopoulos A81 Proteomics and mass spectrometry based non-invasive prenatal testing of fetal health and pregnancy complications George Th. Tsangaris, Athanasios K. Anagnostopoulos A82 Integrated Ecosystem for an Integrated Care model for Heart Failure (HF) patients including related comorbidities (ZENITH) José Verdú, German Gutiérrez, Jordi Rovira, Marta Martinez, Lutz Fleischhacker, Donna Green, Arthur Garson, Elena Tamburini, Stefano Cuomo, Juan Martinez-Leon, Teresa Abrisqueta, Hans-Peter Brunner-La Rocca, Tiny Jaarsma, Teresa Arredondo, Cecilia Vera, Giuseppe Fico, Olga Golubnitschaja, Fernando Arribas, Martina Onderco, Isabel Vara, on behalf of ZENITH consortium A83 Predictive, preventive and personalized medicine in diabetes onset and complication (MOSAIC project) José Verdú, Francesco Sambo, Barbara Di Camillo, Claudio Cobelli, Andrea Facchinetti, Giuseppe Fico, Riccardo Bellazzi, Lucia Sacchi, Arianna Dagliati, Daniele Segnani, Valentina Tibollo, Manuel Ottaviano, Rafael Gabriel, Leif Groop, Jacqueline Postma, Antonio Martinez, Liisa Hakaste, Tiinamaija Tuomi, Konstantia Zarkogianni, on behalf of MOSAIC consortium A84 Possibilities for personalized therapy of diabetes using in vitro screening of insulin and oral hypoglycemic agents Igor Volchek, Nina Pototskaya, Andrey Petrov A85 The innovative technology for personalized therapy of human diseases based on in vitro drug screening Igor Volchek, Nadezhda Pototskaya, Andrey Petrov A86 Bone destruction and temporomandibular joint: predictive markers, pathogenetic aspects and quality of life Ülle Voog-Oras, Oksana Jagur, Edvitar Leibur, Priit Niibo, Triin Jagomägi, Minh Son Nguyen, Chris Pruunsild, Dagmar Piikov, Mare Saag A87 Sub-optimal health management – global vision for concepts in medical travel Wei Wang A88 Sub-optimal health management: synergic PPPM-TCAM approach Wei Wang A89 Innovative technologies for minimal invasive diagnostics Andreas Weinhäusel, Walter Pulverer, Matthias Wielscher, Manuela Hofner, Christa Noehammer, Regina Soldo, Peter Hettegger, Istvan Gyurjan, Ronald Kulovics, Silvia Schönthaler, Gabriel Beikircher, Albert Kriegner, Stephan Pabinger, Klemens Vierlinger A90 Rare disease diobanks for personalized medicine Ayşe Yüzbaşıoğlu, Meral Özgüç, Member of EuroBioBank - European Network of DNA, Cell and Tissue Banks for Rare Disease
La structure génétique à fine échelle de population en France
La structure génétique à fine échelle des populations humaines est intéressante pour deux raisons principales : 1) elle reflète des événements historiques et démographiques, 2) elle informe la recherche sur les études d’association de maladies. Cette thèse a pour objectif de procéder à une analyse approfondie de la structure génétique de la population de France métropolitaine dans un premier temps, en de façon plus détaillée de la population du nord-ouest de la France, et de mettre en lumière les événements historiques, démographiques et culturels qui l’ont façonnés, en tirant parti de trois jeux de données (SU.VI.MAX/3C et PREGO). Au niveau de la France, nous rapportons la corrélation entre les données génétiques et les lieux de naissance d’individus appartenant à deux cohortes françaises indépendantes (1 414 et 770 individus) et identifions six groupes, concordants entre les jeux de données. La deuxième étude tire parti de la cohorte PREGO, qui comprend 3 234 personnes ayant trois générations d’ascendance liée à des régions spécifiques du nord-ouest de la France. Je révèle une structure à fine échelle à un niveau sans précédent (154 sous-populations).historique de la France et des explications potentielles de la prévalence de différentes maladies dans cette région du nord-ouest. Dans l’ensemble, mes travaux de thèse indiquent des niveaux substantiels de stratification de la population dans une région géographiquement limitée, probablement en raison de différents antécédents démographiques dans la région.Fine-scale genetic structure in human populations is interesting for two main reasons: 1), it reflects historical and demographic events, 2) it informs research on disease association studies. This thesis aims to perform a thorough analysis of the genetic structure of the population from continental France, in particular Northwestern France, and shed light on the historical, demographic and cultural events that have shaped it, by taking advantage of three genome-wide datasets (SU.VI.MAX/3C and PREGO) At the country level we report the correlation between genetic data and birthplaces of individuals in two independent French cohorts (1,414 and 770 individuals in SU.VI.MAX and 3C, respectively) and identify six clusters, concordant between datasets, and may correspond to ancient political, cultural and geographical borders. The second study takes advantage of the PREGO cohort including 3,234 individuals with three generations of ancestry linked to specific regions of Northwestern France and reveals fine-scale structure at an unprecedented level (154 subpopulations). The resulting genetic clusters and the characterisation of their effective population size and ancestry proportions compared to other European groups provide important and novel insights into the historical peopling of France and potential explanations for different disease prevalence within this northwestern region. Overall, my thesis work indicate substantial levels of population stratification within a geographically limited region likely caused by different demographic histories across the region
Role of apelin in the regulation of glucose metabolism and of the cardiovascular system
Apelina jest jedną z aktywnych biologicznie adipokin syntetyzowanych
przez tkankę tłuszczową. Należy do grupy
białek transbłonowych sprzężonych z białkiem G i wykazuje
największą homologię z receptorem angiotensyny II. Badania
ostatnich lat wykazały obecność apeliny w różnych narządach,
takich jak: układ pokarmowy, układ krążenia, mózg,
płuca, wątroba, śledziona, nerki, gruczoł sutkowy człowieka,
tkanka tłuszczowa i łożysko. Apelina poprzez działanie na
swoisty receptor jest zaangażowana w regulację funkcji
układu sercowo-naczyniowego, gospodarki wodno-elektrolitowej
(kontrola łaknienia i przyjmowania płynów), szlaku
sygnałowego w centralnym układzie nerwowym, odpowiedzi
immunologicznej, a także w proces embriogenezy i stymulację
angiogenezy. Apelina wydaje się odgrywać istotną rolę
w patofizjologii chorób metabolicznych. Wykazano, że poprawia
wrażliwość komórek na insulinę i może opóźniać rozwój
zaburzeń metabolicznych towarzyszących otyłości. Ponadto,
jej silne działanie inotropowo dodatnie oraz hipotensyjne
powoduje, że może ona znaleźć zastosowanie w leczeniu
chorób sercowo-naczyniowych i nadciśnienia tętniczego.Apelin is one of biologicaly active adipokines synthesised by
adipose tissue. It belongs to the group of transmembrane G
protein-coupled proteins and has the highest homology to
the angiotensin II receptor. Recent studies has shown the
presence of apelin in many different organs, such as: digestive
system, circulatory system, brain, lungs, liver, spleen, kidney,
human mammary gland, adipose tissue, and placenta.
Apelina by acting at specific receptor is involved in the
regulation of the cardiovascular, gastrointestinal and immune
functions, hypothalamus-hypophysis axis modulation, as
well as fluid homeostasis (water intake control), embryonal
development and angiogenesis. Apelina seems to play an
important role in the pathophysiology of metabolic diseases.
It has been shown that apelin improves insulin sensitivity
and delays the development of obesity-related metabolic
disorders. Furthermore, the strong positive inotropic and
hypotensive effect of apelin may find application in the
treatment of cardiovascular diseases and hypertensio
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
Recent advances in immunology enabled the characterization of several signal transmitting pathways responsible for proper cytokine and chemokine signaling. Among them, Janus kinases (JAKs) are essential components of receptor activation systems. The discovery of JAK kinases enabled the synthesis of JAK kinase inhibitors (JAKi or Jakinibs), which have proven to be efficacious in the treatment of hematologic malignancies and several rheumatological disorders and continue to be investigated in many clinical indications. Blocking multiple cytokines belonging to several cytokine families with a single small molecule may, however, create a potential risk for the patients. Recently, a higher risk of thromboembolic complications, namely, deep vein thrombosis and pulmonary embolism, has been recognized as the main concern during treatment with Jakinibs. At present, it is not entirely clear whether this increased risk is related to direct cytokine blockade, the presence of concomitant diseases in treated patients or other unknown circumstances that work together to increase the risk of this side effect. In this review, we discuss data on the risk of thromboembolic side effects, with special emphasis on the mechanism that may be responsible for this increased risk. Many indirect data indicate that higher thromboembolic risk may be related to the specificity of JAK inhibitor action, such that preferentially blocking one signaling pathway upsets the balance between pro and anti-thrombotic activities
Transcription of intragenic CpG islands influences spatiotemporal host gene pre-mRNA processing
Cytometric Characterization of Main Immunocompetent Cells in Patients with Systemic Sclerosis: Relationship with Disease Activity and Type of Immunosuppressive Treatment
Systemic sclerosis (SSc) is a connective tissue disease that is characterized by widespread skin and internal organ fibrosis vasculopathy and immune response abnormalities, including T, B, natural killer (NK), and natural killer T (NKT) cell involvement. The aim of the study was to investigate the immune cell profile in patients with systemic sclerosis in relation to the disease activity, severity, and antibody presence and their relation to the type of immunosuppressive treatment. Cytometric examination identified following cell lines: B cells (Breg, B memory, B mature) and plasmablasts, T cell, T double positive—Tdp, T double negative—Tdn, NK, and NKT cell and monocytes. The disease severity and activity were assessed based on the Medsger and the EULAR Scleroderma Trials and Research Group (EUSTAR) 2017 scales respectively. In the study, SSc patients were characterized by higher total lymphocyte count parallel to increased frequency of Ts and Th cells. In SSc patients, increment of Tdp and reduction of Tdn as well as NK and NKT cells were observed. Additionally in SSc patients the reduction of B memory was noted. Head to head comparison between cyclophosphamide (CYC) and mycophenolate mofetil (MMF) treatment showed a reduction of CD19+ cells, but increment of plasmablasts in CYC treated patients